Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial

Hiroaki Ogata 1, Naoko Shimofurutani2, Tadashi Okada2, Hisashi Nagamoto3 and Tadao Akizawa4

1Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan, 2Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd, Osaka, Japan, 3Medical Affairs, Otsuka Pharmaceutical Co. Ltd, Tokushima, Japan and 4Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Correspondence to: Hiroaki Ogata; E-mail: ogatah@med.showa-u.ac.jp

ABSTRACT

Background. Loop diuretics are used to manage fluid retention in patients with end-stage kidney disease undergoing hemodialysis (HD). This randomized, double-blind, placebo-controlled, Phase 2 trial evaluated the efficacy and safety of tolvaptan, a vasopressin V2 receptor antagonist, in Japanese HD patients.

Methods. A total of 124 patients (24-h urine volume ≥500 mL) on thrice-weekly HD were randomized to receive oral tolvaptan 15 mg/day (n = 40), tolvaptan 30 mg/day (n = 40) or placebo (n = 44) for 24 weeks. Efficacy endpoints were change from baseline in 24-h urine volume, total fluid removal by HD per week and interdialytic weight gain (IDWG). Safety was assessed...
Conclusions. Tolvaptan significantly sustained diuretic action for 24 weeks in HD patients but did not reduce total fluid removal by HD per week and IDWG to the same extent.

Keywords: aquaretic, diuretic, end-stage kidney disease, hemodialysis, tolvaptan

INTRODUCTION

In patients with end-stage kidney disease (ESKD), decreased kidney function causes fluid retention and increased blood pressure (BP) and contributes to end-organ damage. Although hemodialysis [HD; including hemodiafiltration (HDF)] effectively improves uremia and fluid retention in ESKD patients, intermittent rapid fluid removal and associated intradialytic hypotension are hypothesized to cause further renal injury and accelerate the loss of residual kidney function (RFK). This, in turn, results in decreased urine volume and increased fluid overload [1, 2], thus increasing the need for rapid fluid removal during dialysis. Diuretics are frequently used to control fluid retention in ESKD patients undergoing HD [3]. However, the efficacy of loop diuretics has been reported to be insufficient in patients with advanced kidney disease [4–6] and toxicity concerns limit their use at high doses [5]. Thus an unmet need exists for new agents to effectively manage fluid retention in HD patients refractory to conventional diuretics.

Unlike loop diuretics, tolvaptan (Otsuka Pharmaceutical, Tokyo, Japan), an oral aquaretic agent, selectively antagonizes arginine vasopressin V₂ receptors and increases free water excretion by inhibiting water reabsorption in the collecting duct [7]. Tolvaptan is currently approved for hyponatremia in heart failure and the syndrome of inappropriate secretion of antidiuretic hormone in the USA and 45 other countries [8] and for volume overload in heart failure or hepatic cirrhosis in patients who are refractory to diuretics in Japan and some Asian countries [9, 10]. In addition, tolvaptan has recently become clinically available for the treatment of autosomal dominant polycystic kidney disease (ADPKD) in Japan, the European Union, the USA and other countries [11–13]. A pilot study revealed that tolvaptan increased urine volume in patients with kidney failure on peritoneal dialysis [14]; however, the efficacy of tolvaptan in HD patients remains to be investigated and it is not yet approved for use in kidney failure.

Based on the hypothesis that tolvaptan could be expected to induce diuresis even in HD patients, we conducted a randomized controlled trial to assess the efficacy and safety of tolvaptan in this population.

MATERIALS AND METHODS

Objectives

To investigate the long-term sustainability of tolvaptan in increasing 24-h urine volume and controlling fluid removal by HD and interdialytic weight gain (IDWG), tolvaptan or placebo was administered for 24 weeks to patients undergoing HD. Additional objectives included the evaluation of safety and the exploratory efficacy outcomes of treatment with tolvaptan.
Study design

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, 24-week, Phase 2 trial was conducted at 44 sites in Japan from 22 January 2015 to 30 May 2016. The trial comprised screening (1–14 days), pretreatment observation (28 days), treatment (24 weeks) and posttreatment observation (3–17 days after Day 7 assessments of Week 24 of the treatment period) periods (Supplementary data, Figure S1). The trial was conducted in accordance with the Declaration of Helsinki, the Pharmaceutical Affairs Law and the Ordinance on Good Clinical Practice and was approved by the institutional review board at each study site. Written informed consent was obtained from all patients before screening. The trial is registered at ClinicalTrials.gov (NCT02331680).

Patients

Major inclusion criteria were thrice-weekly HD/HDF, 24-h urine volume ≥500 mL/day and age 20–80 years inclusive. Key exclusion criteria were urinary tract complications due to stenosis, urolithiasis, tumor or other causes; cardiac failure (New York Heart Association Class IV) and liver disorders, such as chronic hepatitis or drug-induced liver injury. Further details are presented in the Supplementary data, Table S1.

Treatment

Eligible patients were randomized in a 1:1:1 ratio to receive tolvaptan 15 or 30 mg/day or placebo for 24 weeks. To minimize bias, treatment allocation was stratified by urine osmolality (≥290/<290 mOsm/L) before HD in the pretreatment observation period. An independent treatment allocation manager prepared a master random allocation table using SAS 9.2 (SAS Institute Japan, Tokyo, Japan) and coded the study drug as per the operating procedures of randomization. The allocation table was sealed by the treatment allocation manager immediately after completion of treatment randomization and was kept under strict control until unblinding. The investigators, patients and trial staff were blinded to treatment randomization.

Tablets of tolvaptan (15/30 mg) or placebo, indistinguishable from each other, were administered once daily after breakfast on off-dialysis days for 24 weeks. To prevent rapid diuresis, patients in the tolvaptan 30 mg group were initiated on a once-daily dose (on off-dialysis days) of 15 mg for the first week followed by 30 mg once daily for 23 weeks. Any drug or food having potent inhibition or induction of cytochrome P450 3A4 (CYP3A4) was prohibited during the study period because CYP3A4 metabolizes tolvaptan. Initiation of any other diuretics or blood purification therapies during the study was not permitted and patients taking diuretics before enrollment were maintained on the same dose and regimen throughout the study period or until study withdrawal.

Endpoints

Efficacy. The main efficacy endpoints were changes from baseline in 24-h urine volume, total fluid removal by HD per week and IDWG. Exploratory efficacy endpoints (Supplementary data, Table S2) included dry weight (target body weight) by HD, frequency of medical treatment for muscle cramps, frequency of medical treatment for a decrease in BP during HD, number of times systolic BP dropped by ≥20 mmHg or by ≥30 mmHg during HD, lowest systolic and diastolic BP during HD, degree of postdialysis malaise and quality of life (QoL)-related outcomes, including the Kidney Disease QoL Short Form (KDQoL-SF, version 1.3) with ESKD-targeted areas and 36-item health survey and psychological burden due to fluid intake restriction.

Safety. Safety was assessed via the incidence of treatment-emergent adverse events (TEAEs), laboratory tests (Supplementary data, Table S3), vital signs and a 12-lead electrocardiogram (ECG).

Statistical analysis

After unblinding, the data were used for the analysis. The efficacy analysis set included all patients with available efficacy data who received one dose of the study drug. The safety analysis set included all patients who received one dose of the study drug. Because this was an exploratory trial, the sample size was not statistically estimated. However, the number of patients for enrollment was set based on the feasibility of the trial and the availability of statistical analysis for the data. Subgroup analysis was performed for the change in 24-h urine volume from baseline over 24 weeks by concomitant use of diuretics, urine osmolality, underlying disease, complicating diabetes, daily urine volume at the introduction of HD or pretreatment observation period, HD history and psychological burden due to fluid restriction as stratification factors. The change from baseline to the end-of-study assessment in main efficacy endpoints was compared between the placebo group and each tolvaptan group using the unpaired/Student’s t-test. The point estimates of the differences in each of these comparisons and their 95% confidence intervals (CIs) were calculated. Multiplicity adjustment was not performed because of the exploratory design of this trial. For the analysis of the efficacy variables at the end-of-study assessment, missing values were imputed using the last
observation carried forward (LOCF) method. Mixed-model analyses for the change from baseline at each time point were also conducted using the compound symmetry covariance structure for the main efficacy endpoints. Furthermore, post hoc analyses were performed—two sensitivity analyses for missing data at the end-of-study assessment for main efficacy endpoints using baseline value and multiple imputation methods and interaction analyses between the change in 24-h urine volume from baseline at the end-of-study assessment by stratification factors and treatment groups (combined tolvaptan versus placebo). The significance level was 5% (two-sided). Analyses were performed using SAS 9.3 (SAS Institute Japan, Tokyo, Japan).

RESULTS

Patient disposition and baseline characteristics

Of the 152 patients screened, 124 were randomly assigned to the three groups: tolvaptan 15 mg/day (n = 40), tolvaptan 30 mg/day (n = 40) or placebo (n = 44) (Figure 1). Ninety-nine patients completed and 25 patients discontinued the trial, with more patients discontinuing in the placebo group [15/44 (34.1%)] than in the tolvaptan groups [10/80 (12.5%)]. The most frequent reason for discontinuation was adverse events [3/40 (7.5%)] in the tolvaptan 15 mg group and met protocol withdrawal criteria in the tolvaptan 30 mg [2/40 (5.0%)] and placebo [5/44 (11.4%)] groups (Figure 1). One patient in each tolvaptan group was excluded from all data sets because of the loss of source documents at the site, and one patient in the placebo group was excluded from the efficacy analysis set because of unavailability of efficacy data. Demographics and baseline characteristics were generally similar across treatment groups (Table 1). Baseline concomitant use of diuretics was consistent across groups.

Efficacy outcomes

24-h urine volume. The 24-h urine volume in the placebo group showed a consistent decrease from baseline at all time points assessed (Figure 2a). In contrast, 24-h urine volume in both the tolvaptan groups increased from Week 2 and was consistently higher versus the placebo group through the treatment period (Figure 2a), with a significant difference from placebo in the mean change from baseline [tolvaptan 15 mg: 429.1 mL (95% CI 231.0–627.2); P < 0.0001 and tolvaptan 30 mg: 371.6 mL (95% CI 144.1–599.2); P = 0.0017] at end of treatment (Table 2). On subgroup analysis, 24-h urine volume in the placebo group decreased regardless of the concomitant use of loop diuretics, while the diuretic effect of tolvaptan was confirmed in patients in both subgroups (Supplementary data, Figure S2 and Table S4). Although no obvious difference in the effect of tolvaptan was confirmed using other stratification factors (Supplementary data, Tables S5–S8 and Tables S10–S11), the interaction analysis between daily urine volume in the pretreatment observation period and treatment group was significant (P = 0.0018) (Supplementary data, Table S9) and the increase in 24-h urine volume was higher among patients in the higher pretreatment daily urine volume category than in the tolvaptan group. The increase in 24-h urine volume by tolvaptan was also confirmed by mixed-model analysis (Supplementary data,
were not included because of missing data in the pretreatment observation period. Efficacy and safety of tolvaptan in HD 5

Table S12). The results of post hoc analysis for 24-h urine volume by baseline value and multiple imputation methods were similar to those by the LOCF method (Supplementary data, Tables S15 and S16).

Total fluid removal by HD per week. From Weeks 8 to 24, the weekly total fluid removal by HD continuously increased in the placebo group, while it plateaued in the tolvaptan groups (Figure 2b). At the end of treatment, the mean change from baseline was not significantly different in the tolvaptan groups versus the placebo group [tolvaptan 15 mg: -613.6 mL (95% CI -1527.4–300.1); P = 0.1852 and tolvaptan 30 mg: -724.2 mL (95% CI -1588.6–140.3); P = 0.0994] (Table 2). The results from the mixed-model analysis are presented in the Supplementary data, Table S13. The results of post hoc analysis for the weekly total fluid removal by HD by baseline value and multiple imputation methods were similar to those by the LOCF method (Supplementary data, Tables S15 and S16).

Other outcomes. A favorable trend toward a lower frequency of medical treatment for muscle cramps was observed in patients who received tolvaptan versus placebo (Supplementary data, Figure S3). No notable differences were observed between the placebo and tolvaptan groups in achievement of dry weight by HD (Supplementary data, Table S17); frequency of medical treatment for a decrease in BP (Supplementary data, Tables S18 and S19); lowest systolic and diastolic BP (Supplementary data, Table S20); number of times systolic BP decreased by ≥30 mmHg during HD (Supplementary data, Tables S21 and S22); psychological burden due to fluid intake restriction (Supplementary data, Table S23); KDQoL-SF overall score, including ESKD-targeted areas (Supplementary data, Table S24), 36-item health survey (Supplementary data, Table S25) and Question 2 or 22 (Supplementary data, Table S26) and degree of malaise after HD (Supplementary data, Tables S27–S29).
Overall 100, 114 and 113 TEAEs were observed in 87.2% (34/39), 97.4% (38/39) and 77.3% (34/44) of patients in the tolvaptan 15 mg, tolvaptan 30 mg and placebo groups, respectively. The most frequently observed TEAEs in any treatment group were nasopharyngitis, diarrhea, vomiting, contusion and thirst (Table 3). Serious TEAEs were observed in 6 (15.4%), 7 (17.9%) and 10 (22.7%) patients in the tolvaptan 15 mg, tolvaptan 30 mg and placebo groups, respectively (Supplementary data, Table S30). TEAEs leading to discontinuation were reported in 4 (10.3%), 0 (0%) and 3 (6.8%) patients in the tolvaptan 15 mg, tolvaptan 30 mg and placebo groups, respectively.

**Safety**

![FIGURE 2: (a) Mean ± SD change in 24-h urine volume from baseline to each time point during the treatment period (efficacy population) and (b) weekly fluid removal during HD. Only patients with both nonmissing baseline values and nonmissing values at each time point were included in the analysis.](https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfaa148/5903094)
| End points                                      | Change from baseline | Difference from placebo group | n*  |
|------------------------------------------------|----------------------|-------------------------------|-----|
| **Change from baseline**                       | Mean ± SD            | Point estimate (95% CI)       | t-test P-value |
| **Treatment group**                            |                      |                               |                |
| 24-h urine volume (mL)                         |                      |                               |                |
| Tolvaptan 15 mg                                | 169.2 ± 422.2        | 429.1 (231.0–627.2)           | <0.0001        |
| Tolvaptan 30 mg                                | 111.8 ± 557.7        | 371.6 (144.1–599.2)           | 0.0017         |
| Placebo                                        | –259.9 ± 463.8       |                               |                |
| Total volume of fluid removal by HD per week (mL) |                      |                               |                |
| Tolvaptan 15 mg                                | 485.9 ± 1979.3       | –613.6 (–1527.4–300.1)        | 0.1852         |
| Tolvaptan 30 mg                                | 375.4 ± 1721.8       | –724.2 (–1588.6–140.3)        | 0.0994         |
| Placebo                                        | 1099.5 ± 2160.5      |                               |                |
| IDWG, 2-day interval (%)                       |                      |                               |                |
| Tolvaptan 15 mg                                | 0.38 ± 1.80          | –0.37 (–1.19–0.45)            | 0.3720         |
| Tolvaptan 30 mg                                | 0.08 ± 1.62          | –0.67 (–1.45–0.11)            | 0.0927         |
| Placebo                                        | 0.75 ± 1.91          |                               |                |

*n* Number of patients with both nonmissing values at baseline and at the end of the treatment period.

Patient numbers with complete data: 24-h urine volume: tolvaptan 15 mg, n = 33; tolvaptan 30 mg, n = 35 and placebo, n = 29; total volume of fluid removal: tolvaptan 15 mg, n = 33; tolvaptan 30 mg, n = 36 and placebo, n = 30; IDWG: tolvaptan 15 mg, n = 33; tolvaptan 30 mg, n = 36 and placebo, n = 30.

---

Table 3. Incidence of TEAEs occurring in ≥5% of patients in any treatment group (safety analysis set)

| TEAEs                                      | Tolvaptan 15 mg (n = 39), n (%) | Tolvaptan 30 mg (n = 39), n (%) | Placebo (n = 44), n (%) |
|--------------------------------------------|---------------------------------|---------------------------------|-------------------------|
| Total number of patients with TEAEs        | 34 (87.2)                       | 38 (97.4)                       | 72 (92.3)               |
| Infections and infestations                |                                 |                                 |                         |
| Nasopharyngitis                            | 9 (23.1)                        | 14 (35.9)                       | 23 (29.5)               |
| Folliculitis                               | 0 (0.0)                         | 2 (5.1)                         | 2 (2.6)                 |
| Injury, poisoning and procedural complications |                                 |                                 |                         |
| Contusion                                  | 1 (2.6)                         | 7 (17.9)                        | 8 (10.3)                |
| Shunt stenosis                             | 0 (0.0)                         | 2 (5.1)                         | 2 (2.6)                 |
| Wound                                      | 2 (5.1)                         | 0 (0.0)                         | 2 (2.6)                 |
| Gastrointestinal disorders                 |                                 |                                 |                         |
| Diarrhea                                   | 1 (2.6)                         | 5 (12.8)                        | 6 (7.7)                 |
| Vomiting                                   | 2 (5.1)                         | 4 (10.3)                        | 6 (7.7)                 |
| Investigations                             |                                 |                                 |                         |
| Blood potassium increased                  | 2 (5.1)                         | 0 (0.0)                         | 2 (2.6)                 |
| BP decreased                               | 3 (7.7)                         | 1 (2.6)                         | 4 (5.1)                 |
| Musculoskeletal and connective tissue disorders |                                 |                                 |                         |
| Musculoskeletal pain                       | 3 (7.7)                         | 0 (0.0)                         | 3 (3.8)                 |
| Skin and subcutaneous tissue disorders     |                                 |                                 |                         |
| Eczema                                     | 0 (0.0)                         | 2 (5.1)                         | 2 (2.6)                 |
| Miliaria                                   | 0 (0.0)                         | 2 (5.1)                         | 2 (2.6)                 |
| General disorders and administration site conditions |                                 |                                 |                         |
| Thirst                                     | 4 (10.3)                        | 3 (7.7)                         | 7 (9.0)                 |
| Cardiac disorders                          |                                 |                                 |                         |
| Angina pectoris                            | 2 (5.1)                         | 0 (0.0)                         | 2 (2.6)                 |
| Nervous system disorders                   |                                 |                                 |                         |
| Headache                                   | 2 (5.1)                         | 1 (2.6)                         | 3 (3.8)                 |
| Metabolism and nutrition disorders         |                                 |                                 |                         |
| Hypoglycemia                               | 0 (0.0)                         | 2 (5.1)                         | 2 (2.6)                 |
| Vascular disorders                         |                                 |                                 |                         |
| Hypertension                               | 2 (5.1)                         | 0 (0.0)                         | 2 (2.6)                 |
| Blood and lymphatic system disorders       |                                 |                                 |                         |
| Iron deficiency anemia                     | 2 (5.1)                         | 0 (0.0)                         | 2 (2.6)                 |
| Psychiatric disorders                      |                                 |                                 |                         |
| Insomnia                                   | 2 (5.1)                         | 0 (0.0)                         | 2 (2.6)                 |

TEAEs were coded from the Medical Dictionary for Regulatory Activities version 19.0.
The predominant effect of loop diuretics is to inhibit the sodium–potassium–chloride (2Cl\(^-\)/K\(^+\)/Na\(^+\)) cotransporter at the apical membrane of the thick ascending limb of Henle, the loop diuretics must be secreted into the lumen of the urinary tract at the proximal tubules [15, 16]. In patients with kidney failure, impaired renal tubular function may decrease the secretion of loop diuretics into the tubular lumen, causing an insufficient delivery of loop diuretics. Furthermore, reduced renal blood flow in the ascending limb of the medulla may cause renal ischemia, leading to inefficient Na\(^+\) reabsorption [17, 18]. Therefore an impaired loop of Henle in the medulla combined with insufficient loop diuretic delivery could be responsible for resistance to loop diuretics in ESKD patients [5, 15, 19]. In contrast, tolvaptan antagonizes vasopressin V\(_2\) receptors located in the basolateral membrane of the renal collecting ducts [17], indicating that tolvaptan is delivered through renal blood flow and not glomerular filtrate. Additionally, the collecting ducts are considered more resistant to ischemia and hypoxia owing to a lower oxygen requirement compared with the loop of Henle. Thus their function is relatively preserved even in ESKD patients [6]. Tolvaptan is therefore expected to work even in HD patients with severely impaired RKF, provided the renal blood flow is maintained. Second, loop diuretics are known to decrease renal blood flow [18], whereas tolvaptan increases it [17]. Since loop diuretics have a strong natriuretic action, they are likely to cause a decrease in extracellular Na\(^+\) levels and intravascular volume, consequently activating the renin–angiotensin system (RAS) and sympathetic tone. In contrast, tolvaptan induces aquaresis without significant urinary Na\(^+\) loss and therefore is likely to affect neither RAS nor sympathetic tone [17, 20]. Interestingly, RAS inhibition is associated with better preservation of RKF in HD patients [21]. Taken together, the differences in mode and site of action and route of delivery between tolvaptan and loop diuretics may enable tolvaptan to exhibit its aquaretic action even in patients with reduced kidney function or electrolyte abnormality. This could also explain the significantly higher change from baseline in 24-h urine volume in both the tolvaptan groups versus in the placebo group.

Of note, no significant decrease was observed in IDWG and total fluid removal by HD in the tolvaptan groups, especially in the early treatment period, in spite of significant increases in 24-h urine volume. We hypothesize that the aquaretic action of tolvaptan initially causes an increase in serum osmolarity followed by stimulation of the feeling of thirst. The resultant increase in fluid intake could have abrogated the effect of tolvaptan on IDWG and total fluid removal by HD. This hypothesis could be supported by the fact that no significant changes in serum Na\(^+\) concentration or osmolarity were observed during the treatment period. Furthermore, the patients in this study could excrete fluid to the same extent through urine, as indicated by their 24-h urine volume of \(\geq 500\) mL, suggesting that tolvaptan may not have had definitive effects on total fluid removal by HD and IDWG.

Although urine output achieved by diuretics, such as natriuretics (e.g. loop diuretics) and aquaretics (tolvaptan), is different from that arising from RKF in several ways (e.g. excretion of uremic toxin), their role in adjusting fluid volume in HD patients is similar. High ultrafiltration rates in HD patients are associated with a great risk of all-cause and cardiovascular death [22], suggesting the importance of maintaining urine output in HD patients. The decrease in fluid removal by HD with diuretics is expected to mitigate a rapid change in body fluid volume. Furthermore, tolvaptan is already used effectively in Japan for fluid removal in patients with congestive heart failure (CHF) and chronic kidney disease (at the predialysis stage) [23, 24]. CHF is frequently observed in HD patients, hence tolvaptan may be clinically effective in HD patients with CHF.

Hepatic dysfunction has been reported in tolvaptan clinical trials for ADPKD [11, 13]. In this study, one patient in the tolvaptan 15 mg group reported a mild increase in alanine aminotransferase and aspartate aminotransferase. However, these TEAEs resolved during the study period. The incidence of thirst was lower and that of diarrhea was lower or comparable to that reported in previous tolvaptan clinical trials [11, 13, 25]. No clinically relevant findings were reported in vital signs, ECG and clinical laboratory tests among the groups. No deaths were reported during the trial and the incidence of serious TEAEs and TEAEs leading to the discontinuation of study drugs was similar among the groups. Overall, tolvaptan was well-tolerated during the 24-week treatment period.

This study has some limitations. First, more patients withdrew from this study in the placebo group versus the tolvaptan groups. Therefore the possibility of attrition bias cannot be excluded. Second, only patients with urine volume \(\geq 500\) mL/day were enrolled to include those with a substantial residual urine volume to allow for the tolvaptan action of increasing urine volume. Thus the results from this study could not confirm the effect of tolvaptan on urine volume in oliguric patients with urine volume <500 mL/day. Third, we are unable to discuss the diuretic action of tolvaptan in patients who are severely resistant to loop diuretics based on the results of the current study.
because the dose of the concomitantly used loop diuretics was low (furosemide-equivalent median dose 40 mg/day). Therefore it also remains unclear whether tolvaptan exhibits aquaretic action in patients who are severely resistant to loop diuretics.

This study suggests that tolvaptan is well-tolerated and increases urine volume and preserves urine output for 24 weeks in HD patients. However, it remains unclear if tolvaptan treatment results in a lower volume of fluid removal during HD and IDWG. Further studies are warranted to validate these findings and to define the role of tolvaptan more clearly in improving clinical outcomes, such as deterioration of RKF and cardiovascular mortality, in HD patients.

SUPPLEMENTARY DATA
Supplementary data are available at ndt online.

ACKNOWLEDGEMENTS
The authors sincerely thank the investigators and patients for their participation in the current trial, Kei Hayashi (Headquarters of Clinical Development, Otsuka Pharmaceutical, Tokyo, Japan) for his dedicated effort in performing the trial and Yoshiyuki Shibasaki (Medical Affairs, Otsuka Pharmaceutical, Tokyo, Japan) for his cooperation in the supplemental statistical analysis. Editorial support in the form of medical writing, assembling tables and creating high-resolution images based on the authors’ detailed directions, collating author comments, copyediting, fact checking and referencing was provided by Annirudha Chillar, MD, PhD, of Cactus Communications and was funded by Otsuka Pharmaceutical.

FUNDING
Funding was provided by Otsuka Pharmaceutical (Tokyo, Japan).

AUTHORS’ CONTRIBUTIONS
H.O., T.A., N.S. and T.O. conceived and designed the trial and contributed to data acquisition. N.S. and T.O. analyzed the data. H.O., T.A., N.S., T.O. and H.N. contributed to interpretation of the data and critically revised the manuscript, read and approved the final manuscript and agreed to be accountable for all aspects of the manuscript.

CONFLICT OF INTEREST STATEMENT
H.O. reports consulting fees from Otsuka Pharmaceutical for this work; lecture fees from Kyowa Hakko Kirin, Otsuka Pharmaceutical, Ono Pharmaceutical and Torii Pharmaceuticals; consulting fees from YL Biologics and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology and Japan Society for the Promotion of Science, outside the submitted work. N.S. and T.O. are full-time employees of Otsuka Pharmaceuticals. H.N. was a full-time employee and a member of the employee stock ownership program of Otsuka Pharmaceutical until the end of 2018. T.A. reports consulting fees from Otsuka Pharmaceutical for this work; lecture fees from Chugai Pharmaceutical; consulting fees from Japan Tobacco, GlaxoSmithKline, Nipro and Sanwa Chemical; consulting and manuscript fees from Astellas Pharma and consulting and lecture fees from Bayer Yakuhin, Kissel Pharmaceutical, Ono Pharmaceutical, Fuso Pharmaceutical Industries, Torii Pharmaceutical and Kyowa Hakko Kirin outside the submitted work.

REFERENCES
1. Kurihara M, Hyodo T, Kiyosawa N et al. Study of hemodialysis without water removal for retention of residual renal function [in Japanese]. Kidney Dial 2007; 63: 219–221
2. Liu S, Diao Z, Zhang D et al. Preservation of residual renal function by not removing water in new hemodialysis patients: a randomized, controlled study. Int Urol Nephrol 2014; 46: 83–90
3. Bragg-Gresham JL, Fissell RB, Mason NA et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 2007; 49: 426–431
4. Oh SW, Han SY. Loop diuretics in clinical practice. Electrolyte Blood Press 2015; 13: 17–21
5. Sica DA. Diuretic use in renal disease. Nat Rev Nephrol 2011; 8: 100–109
6. Mori T, Ooba I, Koizumi K et al. Analysis of case reports of tolvaptan administered patients (learning indication of tolvaptan from 9 cases of chronic kidney disease) [in Japanese]. Med Drug J 2012; 48: 756–759
7. Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860–867
8. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099–2112
9. Matsuizaki M, Hori M, Izumi T et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25(Suppl 1): S33–S45
10. Sakaia I, Kawaozoe S, Kajimura K et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 73–82
11. Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407–2418
12. Muto S, Kawano H, Higashihara E et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3/4 trial. Clin Exp Nephrol 2015; 19: 867–877
13. Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017; 377: 1930–1942
14. Hiramatsu T, Hobo A, Hayasaka T et al. A pilot study examining the effects of tolvaptan on residual renal function in peritoneal dialysis for diabetics. Perit Dial Int 2015; 35: 552–558
15. Dusso B, Moussi-Frances J, Morange S et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005; 20: 349–353
16. Wittner M, Di Stefano A, Wagemann P et al. How do loop diuretics act? Drugs 1991; 41(Suppl 3): 1–13
17. Costello-Boerrigter LC, Smith WB, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273–F278
18. Chen HH, Redfield MM, Nordstrom LJ et al. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic
therapy in human heart failure. *Am J Physiol Renal Physiol* 2003; 284: F1115–F1119
19. Brater DC. Diuretic therapy. *N Engl J Med* 1998; 339: 387–395
20. Vilar E, Farrington K. Emerging importance of residual renal function in end-stage renal failure. *Semin Dial* 2011; 24: 487–494
21. Mathew AT, Fishbane S, Obi Y et al. Preservation of residual kidney function in hemodialysis patients: reviving an old concept. *Kidney Int* 2016; 90: 262–271
22. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. *Kidney Int* 2011; 79: 250–257
23. Katsumata M, Hirawa N, Sumida K et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. *Clin Exp Nephrol* 2017; 21: 858–865
24. Uemura Y, Shibata R, Takemoto K et al. Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. *Circ J* 2017; 81: 1736–1738
25. Irazabal MV, Torres VE, Hogan MC et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. *Kidney Int* 2011; 80: 295–301

Received: 18.7.2019; Editorial decision: 14.4.2020